GENELUX (GNLX) stock: insider trades, news & valuation
Heavy sellingShare price and insider trades
GENELUX insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 6 sold $436K of GNLX stock on the open market.
Get emailed when insiders cluster-buy stocks like GNLX
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
GNLX insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | $194K | 7 |
| Q2 2026 | — | 0 | $43K | 6 |
| Q1 2026 | — | 0 | $43K | 6 |
| Q4 2025 | — | 0 | $87K | 6 |
| Q3 2025 | — | 0 | $68K | 6 |
Valuation, profit and volume
Summary
Over the past 12 months, 0 GENELUX Corp insiders reported open-market purchases totaling $0, while 6 insiders reported sales totaling $436K. 3 of 31 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Sep 2SEC | Thomas ZindrickCEO, President | Sell | 34,4631,226,427 held (−3%) | $2.67 | $92K | -4.1% | — |
| Sep 2SEC | Joseph CappelloChief Technical Officer | Sell | 10,257318,480 held (−3%) | $2.74 | $28K | -6.6% | — |
| Sep 2SEC | Yong YuChief Scientific Officer | Sell | 9,683258,688 held (−4%) | $2.75 | $27K | -6.9% | — |
| Aug 4SEC | Thomas ZindrickCEO, President | Sell | 3,0231,260,890 held (−0%) | $2.95 | $9K | -13.2% | — |
| Aug 4SEC | Joseph CappelloChief Technical Officer | Sell | 653328,737 held (−0%) | $2.95 | $2K | -13.2% | — |
| Aug 4SEC | Yong YuChief Scientific Officer | Sell | 653268,371 held (−0%) | $2.94 | $2K | -12.9% | — |
| Jul 2SEC | John W SmitherDirector | Sell | 12,00091,403 held (−12%) | $2.91 | $35K | -12.0% | — |
| Jun 4SEC | Ralph SmallingHead Of Regulatory | Sell | 19267,611 held (−0%) | $2.93 | $563 | -12.6% | — |
| Jun 2SEC | John ThomasDirector | Sell Plan | 10,000472,784 held (−2%) | $2.98 | $30K | -14.1% | — |
| May 12SEC | Thomas ZindrickCEO, President | Sell | 2,798532,051 held (−1%) | $2.94 | $8K | -12.9% | — |
| May 12SEC | Yong YuChief Scientific Officer | Sell | 605149,706 held (−0%) | $2.97 | $2K | -13.8% | — |
| May 12SEC | Joseph CappelloChief Technical Officer | Sell | 605154,549 held (−0%) | $2.97 | $2K | -13.8% | — |
| May 12SEC | Ralph SmallingHead Of Regulatory | Sell | 27067,803 held (−0%) | $2.98 | $805 | -14.1% | — |
| Mar 26SEC | Thomas ZindrickCEO, President | Sell | 3,582534,849 held (−1%) | $2.42 | $9K | +5.8% | — |
| Mar 26SEC | Yong YuSvp, Clinical Development | Sell | 906144,938 held (−1%) | $2.42 | $2K | +5.8% | — |
| Mar 26SEC | Joseph CappelloChief Technical Officer | Sell | 906155,154 held (−1%) | $2.42 | $2K | +5.8% | — |
| Mar 26SEC | Ralph SmallingHead Of Regulatory | Sell | 34568,313 held (−1%) | $2.42 | $835 | +5.8% | — |
| Mar 26SEC | Ralph SmallingHead Of Regulatory | Sell | 24068,073 held (−0%) | $2.51 | $602 | +2.0% | — |
| Mar 3SEC | John ThomasDirector | Sell Plan | 10,000482,784 held (−2%) | $2.90 | $29K | -11.7% | — |
| Dec 11SEC | Thomas ZindrickCEO, President | Sell | 12,673542,940 held (−2%) | $3.33 | $42K | -23.1% | — |
| Dec 11SEC | Thomas ZindrickCEO, President | Sell | 4,509538,431 held (−1%) | $5.37 | $24K | -52.3% | — |
| Dec 11SEC | Yong YuSvp, Clinical Development | Sell | 3,219146,817 held (−2%) | $3.36 | $11K | -23.8% | — |
| Dec 11SEC | Yong YuSvp, Clinical Development | Sell | 973145,844 held (−1%) | $5.37 | $5K | -52.3% | — |
| Dec 11SEC | Joseph CappelloChief Technical Officer | Sell | 973156,060 held (−1%) | $5.37 | $5K | -52.3% | — |
| Dec 11SEC | Joseph CappelloChief Technical Officer | Sell | 1,463157,033 held (−1%) | $3.36 | $5K | -23.8% | — |
| Dec 11SEC | Joseph CappelloChief Technical Officer | Sell | 1,270158,496 held (−1%) | $3.33 | $4K | -23.1% | — |
| Dec 9SEC | Ralph SmallingHead Of Regulatory | Sell | 1,24469,746 held (−2%) | $3.36 | $4K | -23.8% | — |
| Dec 9SEC | Ralph SmallingHead Of Regulatory | Sell | 58069,166 held (−1%) | $3.36 | $2K | -23.8% | — |
| Dec 9SEC | Ralph SmallingHead Of Regulatory | Sell | 34368,823 held (−0%) | $5.37 | $2K | -52.3% | — |
| Dec 9SEC | Ralph SmallingHead Of Regulatory | Sell | 16568,658 held (−0%) | $4.69 | $774 | -45.4% | — |
| Dec 2SEC | John ThomasDirector | Sell Plan | 10,000492,784 held (−2%) | $5.00 | $50K | -48.8% | — |
Insiders at GENELUX Corp
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Thomas ZindrickCEO, President | — | $184K | Sep 2, 2026 | — |
| John ThomasDirector | — | $109K | Jun 2, 2026 | — |
| Yong YuChief Scientific Officer | — | $49K | Sep 2, 2026 | — |
| Joseph CappelloChief Technical Officer | — | $48K | Sep 2, 2026 | — |
| John W SmitherDirector | — | $35K | Jul 2, 2026 | — |
| Ralph SmallingHead Of Regulatory | — | $12K | Jun 4, 2026 | — |
GNLX stock: common questions
Are GENELUX Corp insiders buying GNLX stock?
In the past 12 months, 0 insiders reported open-market purchases of GNLX worth $0.
Are GENELUX Corp insiders selling GNLX stock?
6 insiders reported sales worth $436K over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is GNLX's 52-week range?
Over the past year GNLX has traded between $2.30 and $8.24. It last closed at $2.56 on Oct 9, 2026.